The timing is hard to dissect, as many PR's were only on the old Sohm website, and now they can't be accessed as they've been removed from the new website. Brainwise was technically a little before Aguilar and Rushing were appointed as advisors, might have been a little limited in what they could "say" or contribute...though as you're pointing out they were "advisors." Also as you point out, now they may have more teeth as Officers/Employees/Management/Leadership.
They still seem to be interested in a Brainwise "product" as the most recent quarterly includes an "Omega 3 Oral syrup." (?)
However, whatever happened to Gabapentin? What did Aguilar say about it?
Gabapentin isn't in the Quarterly as a "saleable product." Have they abandoned Gabapentin?
Or do they still plan to offer gabapentin for the nerve "pain"?
SOHM is pleased to announce its newest private label Rx offering of Gabapentin Capsules. It is an anti-epileptic medication that is used to relieve the pain associated with neuropathic conditions. According to data, the US market for Gabapentin is approximately US $270 Mn. $SHMNpic.twitter.com/L8RfeBGyin